利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.011 秒)

    THERAPEUTIC AGENT AND TREATMENT METHOD FOR AMELIORATING UREMIA
    1.
    发明授权
    THERAPEUTIC AGENT AND TREATMENT METHOD FOR AMELIORATING UREMIA 有权
    治疗药物和治疗来解除尿毒症方法

    公开(公告)号：EP1913946B1

    公开(公告)日：2014-03-05

    申请号：EP06767982.9

    申请日：2006-07-07

    申请人： TORAY INDUSTRIES, INC.

    发明人： TAKENAKA, Masahiko ,  YAMANE, Yoshihisa ,  IDA, Nobutaka ,  KURUMATANI, Hajimu

    IPC分类号： A61K31/5578 ,  A61K31/5585 ,  A61P13/12 ,  C07D307/93

    CPC分类号： A61K31/343 ,  A61K31/5578 ,  A61K31/5585 ,  C07D307/93

    摘要： A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I 2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.

    MEDICINE FOR PREVENTING AND TREATING BLEEDING TENDENCY
    3.
    发明公开
    MEDICINE FOR PREVENTING AND TREATING BLEEDING TENDENCY 失效
    MEDIKAMENT ZUR VORBEUGUNG UND BEHANDLUNG DER TENDENZ ZU BLUTUNGEN。

    公开(公告)号：EP0560998A1

    公开(公告)日：1993-09-22

    申请号：EP93906339.2

    申请日：1992-10-08

    申请人： TORAY INDUSTRIES, INC.

    发明人： OKAMOTO, Tasuku N102, 31-17, Tsunishi 1-chome ,  OKANO, Kiyoshi 4-8-211, Ichinomiya 5-chome ,  SATO, Yuichiro ,  IDA, Nobutaka ,  NARUTO, Masanobu H-2, 20-31, Tsunishi 1-chome

    IPC分类号： A61K37/02

    CPC分类号： C07K14/5412 ,  A61K38/204

    摘要： A medicine for preventing and treating bleeding tendency containing IL-6 as an active ingredient. The administration of IL-6 serves to enhance the functions of both blood platelets and hemangioendothelial cells to thereby remedy hemorrhagic diathesis, thus enhancing the hemostatic function. Thus IL-6 is useful as an excellent medicine for preventing and treating bleeding tendency, since it has an activity of efficiently inhibiting the bleeding tendency of a living organism and is per se a physiologically active substance derived from a living organism. Therefore IL-6 is useful in treating various bleeding tendencies, such as one caused by bone marrow inhibition after cancer chemotherapy and radiotherapy, one observed after bone marrow transplantation, one observed in hypoplastic anemia, or one observed in idiopathic thrombocytopenic purpura.

    摘要翻译： 一种用于预防和治疗含有IL-6作为活性成分的出血倾向的药物。 IL-6的施用用于增强血小板和血管内皮细胞的功能，从而补救出血性素质，从而增强止血功能。 因此，IL-6作为预防和治疗出血倾向的优良药物是有用的，因为它具有有效抑制活生物体的出血倾向的活性，并且本身是来自活体的生理活性物质。 因此，IL-6可用于治疗各种出血倾向，如癌症化疗和放疗后骨髓抑制引起的出血倾向，骨髓移植后观察到的一种，发生在发育不全的贫血中观察到的，或者是特发性血小板减少性紫癜观察到的。

    THERAPEUTIC AGENT AND TREATMENT METHOD FOR AMELIORATING UREMIA
    4.
    发明公开
    THERAPEUTIC AGENT AND TREATMENT METHOD FOR AMELIORATING UREMIA 有权
    治疗麻醉品麻醉品牌伦敦伦敦维多利亚ZUR LINDERUNG VONURÄMIE

    公开(公告)号：EP1913946A1

    公开(公告)日：2008-04-23

    申请号：EP06767982.9

    申请日：2006-07-07

    申请人： TORAY INDUSTRIES, INC.

    发明人： TAKENAKA, Masahiko ,  YAMANE, Yoshihisa ,  IDA, Nobutaka ,  KURUMATANI, Hajimu

    IPC分类号： A61K31/5578 ,  A61K31/5585 ,  A61P13/12 ,  C07D307/93

    CPC分类号： A61K31/343 ,  A61K31/5578 ,  A61K31/5585 ,  C07D307/93

    摘要： A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I 2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.

    摘要翻译： 公开了治疗剂和治疗剂可以容易地服用的治疗剂和治疗方法，其副作用较小，并且在医学经济学方面不贵。 用于患有慢性肾功能衰竭的患者的尿毒症治疗剂包括作为有效成分的具有特定结构的前列腺素I 2衍生物，例如贝前列素钠。 用于尿毒症的治疗剂可以改善慢性肾功能衰竭患者的尿毒症，而不伴随副作用，恢复食欲降低，活动改善，体重增加等。 尿毒症的治疗效果是在肾功能衰竭状态下观察到的作为临床症状的尿毒症症状明显缓解或消失，特别是即使肾功能下降进行的状态也是如此。

    REMEDY FOR BONE DISEASES
    7.
    发明公开
    REMEDY FOR BONE DISEASES 失效
    INTERFERON-BETA GEGEN KNOCHENERKRANKUNGEN

    公开(公告)号：EP0783891A1

    公开(公告)日：1997-07-16

    申请号：EP96925093.5

    申请日：1996-07-25

    申请人： TORAY INDUSTRIES, INC.

    发明人： IDA, Nobutaka ,  SUZUKI, Tomohiko ,  KUMAGAI, Emi

    IPC分类号： A61K38/21 ,  A61K45/00

    CPC分类号： A61K38/215 ,  A61K38/21 ,  A61K38/212 ,  A61K38/217

    摘要： By the present invention, the relative action to promote bone formation by IFNβ was proved. The action to inhibit mineralization as shown by interferon γ is not observed with interferon β. Especially, usefulness of interferon β as a drug for treating bone disorders was shown, whose effect for prevention and therapy of bone disorders was confirmed in the bone disorder model animals in terms of increase in the bone volume.
    Further, the possibility of using interferon inducers as drugs for treating bone disorders was discovered.

    摘要翻译： 通过本发明，证明了通过IFNβ促进骨形成的相对作用。 用干扰素γ显示抑制矿化的作用在干扰素β中未观察到。 显示出干扰素β作为治疗骨骼疾病的药物的用途，其在骨骼疾病模型动物中在骨量增加方面证实了对预防和治疗骨骼疾病的作用。 此外，发现使用干扰素诱导剂作为治疗骨骼疾病的药物的可能性。